Table 1.
HLA ligands identified from DLBCL markers and disease-specific HLA ligands
| SUDHL-4 | DB | SUDHL-6 | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IFN-γ | IFN-γ/ decitabine | IFN-γ/ tazemetostat | IFN-γ/ decitabine/tazemetostat | Untreated | IFN-γ | IFN-γ/ decitabine | IFN-γ/ tazemetostat | IFN-γ/ decitabine/tazemetostat | IFN-γ | IFN-γ/ decitabine | IFN-γ/ tazemetostat | IFN-γ/ decitabine/tazemetostat | |
| HLA ligands from proteins used as DLBCL markers | |||||||||||||
| BCL6 | LIHTGEKPY (B*15), RIHSGEKPY (B*15), SQSPQHAEM (B*15), TVHTGEKPY (B*15) | RIHSGEKPY (B*15), SQSPQHAEM (B*15), AITNTKVQY (B*15), TVHTGEKPY (B*15), GAITNTKVQY (B*15) | RIHSGEKPY (B*15), SQSPQHAEM (B*15), TVHTGEKPY (B*15), LIHTGEKPY (B*15) | RIHSGEKPY (B*15) | |||||||||
| CREBBP | AQAPAQSQF (B*15) | ||||||||||||
| CD79A/B | RVQEGNESY (B*15) | RVQEGNESY (B*15) | RVQEGNESY (B*15) | RVQEGNESY (B*15) | LLSAEPVPA (A*02) | DEYEDENLY (B*18), LLSAEPVPA (A*02), TELRVmGF (B*18) | DEYEDENLY (B*18), LLSAEPVPA (A*02), TELRVmGF (B*18) | DEYEDENLY (B*18), LLSAEPVPA (A*02), TELRVMGF (B*18) | DEYEDENLY (B*18), LLSAEPVPA (A*02), TELRVMGF (B*18), DENPQQLKL (B*18) | RVQEGNESY (B*15) | RVQEGNESY (B*15) | RVQEGNESY (B*15) | |
| PAX5 | YSHPQYSSY (B*15) | YSHPQYSSY (B*15) | |||||||||||
| HLA ligands not presented in healthy cells | |||||||||||||
| RGS13 | ATKYGPVVY (B*15) | ATKYGPVVY (B*15) | ATKYGPVVY (B*15) | FENLMATKY (B*18) | ATKYGPVVY (B*15) | ATKYGPVVY (B*15) | |||||||
| E2F8 | PQAPSGPSY (B*15) | PQAPSGPSY (B*15) | QEFDFIKSY (B*18) | QEFDFIKSY (B*18) | QEFDFIKSY (B*18) | PQAPSGPSY (B*15) | PQAPSGPSY (B*15) | ||||||